Literature DB >> 12416741

Late response to cyclosporine in refractory thrombotic thrombocytopenic purpura.

Annamaria Nosari1, Patrizia Bernuzzi, Roberto Corneo, Ester Pungolino, Giuliana Muti, Valentina Rossi, Enrica Morra.   

Abstract

Plasma exchange (PEX) with fresh frozen plasma, usually in association with steroid therapy, has been shown to be the first-line treatment of thrombotic thrombocytopenic purpura. It works by removing ultralarge von Willebrand factor (vWF) multimers and inhibitory antibody and by supplying normal protease. For patients with disease refractory to PEX, there is no standardized treatment. Limited and sporadic success with different therapies (vincristine sulfate, prostacyclin, intravenous immunoglobulins, splenectomy) has been described. We report the case of a woman who developed refractory disease after an initial response to PEX and despite a very high number of PEX procedures performed. Low activity (< 5%) of serum vWF-cleaving protease and a low level of protease inhibitor were documented. The patient had a slow but sustained response when oral cyclosporine was administered concomitantly with PEX, which was slowly tapered. The activity of serum vWF-cleaving protease normalized. At relapse, treatment with cyclosporine, added after the failure of steroids and PEX, led to a lasting response. It is possible that in some cases cyclosporine therapy must be of particularly long duration before being considered ineffective.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12416741     DOI: 10.1007/bf02982800

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  14 in total

1.  Chronic relapsing thrombotic thrombocytopenic purpura: role of therapy with cyclosporine.

Authors:  D Pasquale; R Vidhya; K DaSilva; M F Tsan; L Lansing; G Chikkappa
Journal:  Am J Hematol       Date:  1998-01       Impact factor: 10.047

2.  Refractory thrombotic thrombocytopenic purpura treated with cyclosporine.

Authors:  W R Bachman; J K Brennan
Journal:  Am J Hematol       Date:  1996-01       Impact factor: 10.047

3.  Cyclosporine for thrombotic thrombocytopenic purpura.

Authors:  H Kierdorf; N Maurin; B Heintz
Journal:  Ann Intern Med       Date:  1993-06-15       Impact factor: 25.391

Review 4.  Thrombotic thrombocytopenic purpura and autoimmunity: a tale of shadows and suspects.

Authors:  C Porta; R Caporali; C Montecucco
Journal:  Haematologica       Date:  1999-03       Impact factor: 9.941

5.  Cyclosporin for thrombotic thrombocytopenic purpura after autologous bone marrow transplantation.

Authors:  H van Ojik; D H Biesma; R Fijnheer; R J Hené; H M Lokhorst; S J Rooda; L F Verdonck
Journal:  Br J Haematol       Date:  1997-03       Impact factor: 6.998

6.  Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis.

Authors:  R L Paquette; L Tran; E M Landaw
Journal:  Bone Marrow Transplant       Date:  1998-08       Impact factor: 5.483

7.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

Review 8.  Thrombotic microangiopathy following bone marrow transplantation.

Authors:  A R Pettitt; R E Clark
Journal:  Bone Marrow Transplant       Date:  1994-10       Impact factor: 5.483

9.  Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.

Authors:  P Kalhs; S Brugger; I Schwarzinger; H T Greinix; F Keil; P A Kyrle; P Knöbl; B Schneider; P Höcker; W Linkesch
Journal:  Transplantation       Date:  1995-11-15       Impact factor: 4.939

10.  Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. The Italian Cooperative Group for TTP.

Authors:  E Bobbio-Pallavicini; C Porta; R Centurioni; L Gugliotta; N Vianelli; F Tacconi; A Billio; E Ascari
Journal:  Eur J Haematol       Date:  1994-04       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.